New research uncovers brain changes in Parkinson's disease
Researchers at Karolinska Institutet have discovered new insights into brain changes in Parkinson's disease using advanced ...
Civil Eats16h
Is There Enough Evidence of Health Risks for the EPA to Ban Paraquat?
Thousands of lawsuits cite studies linking paraquat to Parkinson’s disease. The EPA says the evidence doesn't warrant a ban ...
Popular weight-loss drugs show promise in reducing kidney disease complications and mortality
A well-known class of drugs used to manage type 2 diabetes and control weight could offer hope for patients who also struggle ...
Hosted on MSN5d
Study Finds Exenatide Not Beneficial for Parkinson Disease
The glucagon-like peptide-1 receptor agonist exenatide does not yield improvement in measures of Parkinson disease severity, ...
Medscape5d
Despite Early Promise GLP-1 Disappoints in Parkinson’s Disease
Exenatide had no disease-modifying effects in a phase 3 trial Parkinson’s disease, despite earlier evidence from a phase 2 ...
MedPage Today6d
Why Did a GLP-1 Receptor Agonist Fail This Parkinson's Trial?
The GLP-1 receptor agonist exenatide failed to meet its primary outcome in a phase III trial of Parkinson's disease patients.
AstraZeneca’s diabetes drug fails to slow Parkinson’s progression in UCL trial
Researchers concluded that the GLP-1RA showed no ability to slow disease progression in people living with Parkinson’s ...
Diabetes drug similar to Ozempic showed no benefits for patients with Parkinson’s disease
A drug for treating diabetes similar to popular weight-loss medicines such as Ozempic did not show any benefits for people ...